Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Costs | 3 | 2017 | 1193 | 0.950 |
Why?
|
| Angiodysplasia | 1 | 2024 | 22 | 0.880 |
Why?
|
| Antifreeze Proteins | 2 | 2013 | 12 | 0.830 |
Why?
|
| Liver Diseases | 3 | 2023 | 1303 | 0.820 |
Why?
|
| Drug Approval | 3 | 2017 | 818 | 0.780 |
Why?
|
| Drugs, Generic | 2 | 2017 | 456 | 0.780 |
Why?
|
| Mitochondria, Liver | 1 | 2021 | 190 | 0.720 |
Why?
|
| Acetyltransferases | 1 | 2021 | 229 | 0.700 |
Why?
|
| Teicoplanin | 1 | 2019 | 27 | 0.680 |
Why?
|
| Thalidomide | 1 | 2024 | 886 | 0.610 |
Why?
|
| Hypercholesterolemia | 1 | 2025 | 1149 | 0.580 |
Why?
|
| Hemoptysis | 1 | 2019 | 150 | 0.570 |
Why?
|
| Tricuspid Valve | 1 | 2019 | 422 | 0.530 |
Why?
|
| Quantitative Trait Loci | 1 | 2025 | 2140 | 0.530 |
Why?
|
| Aneurysm, False | 1 | 2019 | 264 | 0.520 |
Why?
|
| Endocarditis, Bacterial | 1 | 2019 | 434 | 0.500 |
Why?
|
| Marketing | 1 | 2017 | 225 | 0.500 |
Why?
|
| Cholesterol, LDL | 1 | 2025 | 2393 | 0.490 |
Why?
|
| Government Regulation | 1 | 2017 | 525 | 0.420 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 705 | 0.420 |
Why?
|
| Gastroenterology | 1 | 2019 | 594 | 0.410 |
Why?
|
| Ice | 1 | 2013 | 102 | 0.390 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 1030 | 0.390 |
Why?
|
| Insect Proteins | 1 | 2013 | 253 | 0.380 |
Why?
|
| Commerce | 1 | 2017 | 611 | 0.380 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 1393 | 0.350 |
Why?
|
| Prescription Drugs | 1 | 2017 | 634 | 0.350 |
Why?
|
| Pulmonary Artery | 1 | 2019 | 1935 | 0.340 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2013 | 431 | 0.330 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 1672 | 0.320 |
Why?
|
| Protein Folding | 1 | 2013 | 869 | 0.310 |
Why?
|
| Genome-Wide Association Study | 2 | 2025 | 12807 | 0.290 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 1662 | 0.290 |
Why?
|
| Chronic Disease | 2 | 2024 | 9347 | 0.270 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2024 | 1127 | 0.260 |
Why?
|
| Phlebitis | 1 | 2024 | 34 | 0.230 |
Why?
|
| Health Expenditures | 1 | 2017 | 2387 | 0.230 |
Why?
|
| Infusions, Intravenous | 2 | 2019 | 2229 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 7478 | 0.180 |
Why?
|
| Lipodystrophy, Familial Partial | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2019 | 75 | 0.160 |
Why?
|
| Drug Users | 1 | 2019 | 134 | 0.150 |
Why?
|
| Crystallography, X-Ray | 2 | 2013 | 1947 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2023 | 807 | 0.140 |
Why?
|
| Habits | 1 | 2017 | 147 | 0.130 |
Why?
|
| Vasopressins | 1 | 2017 | 359 | 0.130 |
Why?
|
| PPAR gamma | 1 | 2019 | 483 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2024 | 2599 | 0.130 |
Why?
|
| Economic Competition | 1 | 2017 | 223 | 0.120 |
Why?
|
| Colitis | 1 | 2024 | 1239 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 3737 | 0.120 |
Why?
|
| Pharmacies | 1 | 2017 | 171 | 0.120 |
Why?
|
| Legislation, Drug | 1 | 2017 | 217 | 0.120 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2017 | 347 | 0.120 |
Why?
|
| State Government | 1 | 2017 | 388 | 0.110 |
Why?
|
| Heparin | 1 | 2021 | 1630 | 0.110 |
Why?
|
| Angiography | 1 | 2019 | 1581 | 0.110 |
Why?
|
| Genomics | 2 | 2019 | 5929 | 0.110 |
Why?
|
| Bronchoscopy | 1 | 2019 | 909 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 721 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 2741 | 0.100 |
Why?
|
| Humans | 14 | 2025 | 765956 | 0.090 |
Why?
|
| Outpatients | 1 | 2019 | 1595 | 0.090 |
Why?
|
| Recurrence | 1 | 2024 | 8501 | 0.090 |
Why?
|
| Crystallization | 1 | 2012 | 521 | 0.090 |
Why?
|
| Drug Industry | 1 | 2017 | 791 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2013 | 1210 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2017 | 1064 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2019 | 1403 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2025 | 11888 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2021 | 6610 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8529 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 16047 | 0.060 |
Why?
|
| United States | 3 | 2017 | 72898 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 18071 | 0.050 |
Why?
|
| Adult | 4 | 2023 | 223038 | 0.050 |
Why?
|
| Gene Expression | 1 | 2012 | 7584 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2024 | 65189 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20660 | 0.030 |
Why?
|
| Middle Aged | 2 | 2019 | 223004 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1968 | 0.030 |
Why?
|
| Biopsy | 1 | 2024 | 6763 | 0.020 |
Why?
|
| Male | 2 | 2019 | 363691 | 0.020 |
Why?
|
| Animals | 2 | 2013 | 168759 | 0.020 |
Why?
|
| Female | 2 | 2019 | 396101 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3800 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 171114 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2021 | 4862 | 0.020 |
Why?
|
| Child | 1 | 2023 | 80563 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 81515 | 0.010 |
Why?
|
Concepts
(90)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(32)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_